Today the BIOPRO Baden-Württemberg GmbH released an article on CeGaT’s tumor diagnostics with the title “Personalized tumor diagnosis by high-throughput sequencing” on its website.
The report details the possibilities and advantages of CeGaT’s tumor diagnostics due to high-throughput sequencing. After the analysis of cancer-relevant genes, for example, the attending doctor can customize the treatment for his patients. This can improve chances of cure and medication side effects can be minimized.
Read the article on the website of BIOPRO.